RUBRIK ARIAL BOLD VERSALER 25 PT

1
The top 15 pharmaceuticals in the world 2005
(Billion USD)
Lipitor (Pfizer)
Plavix (BMS)
Nexium (AstraZeneca)
Seretide (GSK)
Zocord (MSD)
Norvasc (Pfizer)
Zyprexa (Lilly)
Risperdal (JJ)
Ogastro/Prevacid (Abbott)
Efexor (Wyeth)
Erypo/Eprex (JJ)
Enbrel (Wyeth)
Zoloft (Pfizer)
Aranesp (Amgen)
Seroquel (AstraZeneca)
Source IMS Health
2
The top 15 pharmaceutical companiessales of
medicines in the world 2005(Billion USD)
Pfizer
GlaxoSmithKline
Sanofi-Aventis
Novartis
JJ
AstraZeneca
Merck Co
Roche
Abbott
BMS
Wyeth
Lilly
Amgen
BI
Takeda
Source IMS Health
3
World pharmaceutical market, allocated on regions
2005
Total global market 602 billion USD
Source IMS Health
4
Total pharmacy market (at ex-factory prices)
average growth rate for the period 19932003 ()
Europe
USA
Japan
Source EFPIA member associations, PhRMA, JPMA
5
Large mergers and acquisitions within the
pharmaceutical industry since 1990
Year
Companies
New name
2005 2004 2003 2001 2001 2000 2000 1999 1999 1997
1996 1995 1995 1995 1994 1991 1990
Yamanouchi Fujisawa Sanofi-Synthélabo
Aventis Pfizer Pharmacia BASF Pharma/Knoll
Abbott Glaxo Wellcome SmithKline Beecham Pfizer
Warner Lambert Pharmacia Upjohn
Searle Hoechst Marion Roussel Rhone-Poulenc
Rorer Astra Zeneca Nycomed Amersham Ciba
Geigy Sandoz Glaxo Burroughs Wellcome Hoechst
Roussel Marion Merrell Dow Pharmacia
Upjohn Janssen Cilag SmithKline
Beecham Rhone-Poulenc Rorer
Astellas Pharma Sanofi-Aventis Pfizer Abbott Glaxo
SmithKline Pfizer Pharmacia Aventis AstraZeneca Ny
comed Amersham Novartis Glaxo Wellcome Hoechst
Marion Roussel Pharmacia Upjohn Janssen-Cilag Sm
ithKline Beecham Rhone-Poulenc Rorer
Source EFPIA
6
Research and development costs for a new medicine
(NCE)
MUSD
Year
7
The pharmaceutical industrys RD expenditures in
Europe, USA and Japan
EURO Billion
Europe
USA
Japan
Year
Source EFPIA member associations, PhRMA, JPMA
8
Pharmaceutical trade balance by country
Country
M EURO
Ireland Switzerland France United
Kingdom Sweden Denmark Germany The
Netherlands Austria Belgium Norway Finland Italy P
ortugal Greece Spain
11 444 9 789 5 900 3 866 3 104 2 648 1
199 56 -619 -628 -648 -1 023 -1 155 -1 356 -2
658 -35 169
Note All data based on SITC 54. France, Norway,
Spain, Switzerland veterinary products
excluded. Grecce, Norway provinsional.
Source EFPIA member associations (official
figures)
9
Total number of introduced new substances (NCEs)
worldwide 1990-2004
Number of NCEs
Europe
USA
Japan
Others
Year
Source EFPIA
10
Total number of substances in active RD 19992005
Number ofsubstances
Year
Source Pharmaprojects
11
Origin of the 23 new molecular entities (chemical
and biological) launched on the world market in
2004
Number
Europe
USA
Japan
Others
Source EFPIA
12
The price level in Sweden for the top 180 selling
pharmaceuticals compared with the corresponding
prices for the same products in other countries
year 2004 (PPP)
Derogation from Swedish pharmaceutical prices for
certain European countries
Difference ()
UK
Italy
Spain
France
Greece
Austria
Iceland
Finland
Norway
Ireland
Portugal
Belgium
Germany
Denmark
Switzerland
Luxembourg
The Netherlands
Source LFN
13
Health care expenditures in percent ofGDP in
selected countries 2003 OECD
Per cent
Source OECDD Health Data 2005, October 05
14
Pharmaceutical expenditures in per cent of GDP in
selected countries 2003
Per cent
Source OECDD Health Data 2004, 3rd edition
15
Pharmaceutical expenditures in percent of health
care expenditures in selected countries 2003
Per cent
Source OECDD Health Data 2005, October 05
16
Pharmaceutical expenditures per capita in
selected countries 2003
PPPs, USD
Per cent
Source OECDD Health Data 2005, October 05